Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial of the Safety and Efficacy of ABX-EGF as Second Line Treatment for Advanced Non-Small Lung Cancer

NCT00101920 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00101920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00101920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial of the Safety and Efficacy of ABX-EGF as Second Line Treatment for Advanced Non-Small Lung Cancer
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
December 31, 2004
Enrollment
50 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, neoplasm metastasis, non-small cell lung cancer